| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25039 |
| Drug |
Trastuzumab Deruxtecan |
| Brand |
Enhertu® |
| Indication |
Trastuzumab deruxtecan (Enhertu®) is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. |
| Rapid review commissioned |
13/06/2025 |
| Rapid review completed |
14/07/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/07/2025 |
| Pre-submission consultation with Applicant |
10/09/2025 |
